Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2018 Jul;103(7):1096-1098.
doi: 10.3324/haematol.2018.196014.

Still a role for second-line chemoimmunotherapy in chronic lymphocytic leukemia?

Jennifer R Brown  1
Affiliations
Editorial

Still a role for second-line chemoimmunotherapy in chronic lymphocytic leukemia?

Jennifer R Brown. Haematologica. 2018 Jul.
No abstract available

PubMed Disclaimer

Comment on

References

    1. Cuneo A, Follows G, Rigolin GM, et al. Efficacy of bendamustine and rituximab as first salvage treatment in chronic lymphocytic leukemia and indirect comparison with ibrutinib: a GIMEMA, ERIC and UK CLL FORUM study. Haematologica. 2018;103(7):1209–1217. - PMC - PubMed
    1. Byrd JC, Brown JR, O’Brien S, et al. Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia. N Engl J Med. 2014;371(3):213–23. - PMC - PubMed
    1. Burger JA, Tedeschi A, Barr PM, et al. Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia. N Engl J Med. 2015;373(25):2425–2437. - PMC - PubMed
    1. Gordon M, Churnetski M, Alqahtani H, et al. Comorbidities Predict Inferior Outcomes in Chronic Lymphocytic Leukemia Treated With Ibrutinib. Cancer. 2018. [In press] - PubMed
    1. Mato AR, Nabhan C, Thompson MC, et al. Toxicities and outcomes of 616 ibrutinib-treated patients in the United States: a real-world analysis. Haematologica. 2018;103(5):874–879. - PMC - PubMed

LinkOut - more resources